Rejuran vs Juvelook: two different bets on your own collagen

What they have in common

Both are injected across an area rather than placed in one spot, both are aimed at skin quality rather than contour, and both work by provoking your own tissue rather than by occupying space.

That last point is the one that matters and the one marketing blurs. Neither is a filler. If the complaint is a hollow or descended tissue, neither is the tool, however they are sold.

Both are also sold as courses, so the number to ask for is the total rather than the price of a session.

What separates them

	Rejuran	Juvelook
Active	Polynucleotides, purified from salmon	Poly-D,L-lactic acid (PDLLA)
Often formulated with	—	Non-crosslinked hyaluronic acid
Proposed mechanism	Adenosine receptor activation, angiogenesis, fibroblast proliferation	Collagen stimulation as the polymer degrades
Onset	Texture and elasticity change described within about three months	Builds over months; trial measured to week 24
Reversible	No	No
Evidence	9 studies, 219 patients, low–moderate quality	1 split-face trial, 33 subjects, on Juvelook Volume for nasolabial folds

Neither can be undone

This is the practical warning both pages carry and it is worth stating once more against each other, because the reassurance patients have about hyaluronic acid filler does not transfer.

Hyaluronidase dissolves hyaluronic acid. It does not remove polynucleotide, and it does not remove PDLLA. In the PDLLA trial, one participant's moderate swelling was treated with an intralesional steroid and hyaluronidase — and that hyaluronidase was acting on the hyaluronic acid component of the product, not on the polymer.

So with either, a conservative first treatment is not caution for its own sake. It is the only exit available.

The evidence, honestly, on both sides

Neither is well evidenced. They are thin differently, which is the useful part.

Polynucleotides have volume: a 2024 systematic review pooled nine studies covering 219 patients. But the studies were rated low to moderate quality, none scored fully on critical appraisal, and of the six reporting wrinkle improvement, half reached statistical significance. The reviewers' conclusion asks for rigorous studies.

PDLLA has one better-designed study and less of it: a 2026 split-face trial in 33 subjects, each person acting as their own control, finding the PDLLA product non-inferior to PLLA — wrinkle severity improvement of −1.37 against −1.20 at week 24, no significant difference. Its most telling figure is that 70% of patients had no preference between the two sides of their own face. The authors say directly that long-term safety needs further study.

That trial is also indirect evidence for Juvelook itself. The product tested was Juvelook Volume (PDLLA with non-crosslinked hyaluronic acid), a separate product in the same range, and it was injected to correct nasolabial folds — not the skin-texture use Juvelook is usually offered for here.

So: more studies of weaker quality against fewer studies of better design, both small. Nothing here establishes either as superior, and anybody who tells you otherwise is not citing this.

What that means when a clinic proposes one

The decision is not going to be settled by evidence, because the evidence does not separate them. What you can do instead:

• Ask which product exactly, in Korean, and check which MFDS portal it is licensed on.
• Ask how many sessions and the total, since both are courses.
• Ask when to judge it — and hold the clinic to that date rather than an earlier one.
• Treat any precise percentage claim as marketing.
• Remember neither can be dissolved, and start conservatively.

If both are proposed together, ask what each is for. No study examines them in combination, so a claim about what the pair achieves is not coming from the literature.

Choosing between them: the same ten checks

The tables above compare how they work. This one is for the consultation: the same ten checks for each, and what to ask where the evidence runs out.

Check	Rejuran	Juvelook
Exact product	Rejuran Healer (리쥬란 힐러); other lines exist, such as Rejuran HB and Rejuran I	Juvelook (쥬베룩); Juvelook Volume is a separate product in the same range
Aimed at	Skin quality: texture, elasticity, fine lines	Skin quality, as it is usually offered in Korea
What the studies measured	Wrinkles, texture and elasticity, across 9 small studies	Nasolabial fold correction against PLLA, to week 24
Evidence for this product	Class evidence for polynucleotides, not for one brand	Indirect: the trial tested Juvelook Volume
Check for your case	Whether the concern is texture rather than a hollow, since neither adds volume	The same, and whether the product contains hyaluronic acid
Recovery	Mild, short-lived pain, swelling, redness, itching or bruising in the review	Mild swelling for three to four days in most trial subjects
Risks	Reported side effects mild and transient; cannot be dissolved	One moderate swelling, treated with steroid and hyaluronidase; long-term safety not yet studied; cannot be dissolved
Visits	A course of several sessions; ask the interval	The trial gave three injections four weeks apart
Cost to compare	The course total, and how many sessions it covers	The course total, and which product it is for
Ask in consultation	Which Rejuran product, how many sessions, what total?	Juvelook or Juvelook Volume, how many sessions, when should I judge it?

A course spread over weeks may not fit a single trip. More than one treatment in one trip covers what can share a visit, flying after treatment covers the gap before a flight, and after you fly home covers the records to bring back.

The bottom line

Rejuran is polynucleotide and Juvelook is PDLLA; both are injected for skin quality, both work through your own tissue response over months, and neither can be dissolved. The evidence is small on both sides — nine low-to-moderate-quality studies in 219 patients for polynucleotides, one split-face trial in 33 people on Juvelook Volume, a sister product, for PDLLA — and does not establish either as better. Choose on product transparency, course cost, and the operator, not on a claimed advantage.